Nexcella Inc. is developing CAR-T cell therapy (NXC-201) specifically for patients with relapsed and refractory AL Amyloidosis, focusing on enhancing treatment safety and efficacy. The company aims to provide accessible, one-time cell-based therapies to improve patient outcomes in this challenging medical condition.
Funding
$8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with relapsed and refractory AL Amyloidosis face limited treatment options and often experience poor outcomes. Current therapies may not be effective in all patients, and the disease can be challenging to manage due to its complex nature and potential for organ damage.
Solution
Nexcella is developing NXC-201, a CAR-T cell therapy designed to provide a targeted treatment option for patients with relapsed and refractory AL Amyloidosis. This investigational cell therapy aims to improve treatment efficacy and safety, offering the potential for a one-time, accessible therapy. By modifying the patient's own T cells to recognize and eliminate amyloid-producing plasma cells, NXC-201 seeks to address the underlying cause of the disease and improve patient outcomes. The NEXICART-2 clinical trial is currently evaluating the safety and efficacy of NXC-201 in this patient population.
Target Audience
The primary target audience includes patients with relapsed and refractory AL Amyloidosis who have not responded to previous treatments, as well as hematologists and oncologists specializing in the treatment of plasma cell disorders.
Features
- CAR-T cell therapy (NXC-201) specifically engineered for AL Amyloidosis
- Targets amyloid-producing plasma cells to reduce organ damage
- Designed to improve treatment safety and efficacy compared to existing options
- Investigational therapy currently in Phase 1/2 clinical trials (NEXICART-2)
- Aims to provide a one-time, accessible cell-based therapy